In Brief: Copley Pharmaceutical
This article was originally published in The Rose Sheet
Copley Pharmaceutical: Asks FDA not to grant three-year market exclusivity to Pharmacia & Upjohn for the sale of OTC Rogaine baldness treatment in a recent letter. Copley was close to having its generic minoxidil product approved for prescription sale when Rogaine achieved OTC status on Feb. 12; since then, Copley said, the company has been preparing new labeling and packaging to reflect the switch. Copley noted that it would be "severely prejudiced if the FDA permits Upjohn to continue to exploit procedural devices to extend its control over the sale of minoxidil." Copley's letter supports a citizen's petition previously filed by Hyman, Phelps & McNamara...
You may also be interested in...
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
Weekly Trademark Review